Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Jin Ying
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06530719CT.gov A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery | — | Not Yet Recruiting | — | — | — |
NCT05153408CT.gov (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | — | Terminated | — | — | — |
NCT04862780CT.gov (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | — | Terminated | — | — | — |
NCT02769286CT.gov Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA | — | Completed | — | — | — |
NCT02759835CT.gov Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Osimertinib (this asset) | Jin Ying | P2 | B · 61 |
| Carboplatin | Nanfang Hospital, Southern Medical University | P4 | BB |
| Nivolumab | Hospital Israelita Albert Einstein | P2 | BB |
| Belagenpumatucel-L (Sk-Lu-1) | NovaRx Corporation | P3 | BB |
| Icotinib | Fuda Cancer Hospital, Guangzhou | P4 | BB |
| Cyclophosphamide | Pfizer | P3 | BB |
| Pralsetinib, Trans- | Hoffmann-La Roche | P3 | BB |
| Rivoceranib | Fuzhou General Hospital | P3 | BB |
| Trastuzumab | Cancer Research UK | P2/3 | B |
+39 more in the Lung Neoplasm cohort
Other indications for Osimertinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 71 |
| Lung Adenocarcinoma | — | P2 | BB · 69 |
| Hepatocellular Carcinoma | — | P3 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Osimertinib in Lung Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/osimertinib-lung-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →